# SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

## CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 29, 2020

OptimizeRx Corporation (Exact name of registrant as specified in its charter)

Nevada	001-38543	26-1265381
(State or other jurisdiction	(Commission File Number)	(I.R.S. Employer
of incorporation)		Identification No.)
400 Water Street, Suite 200, Rochester, MI		48307
(Address of principal executive offices)		(Zip Code)
Registra	nt's telephone number, including area code: 248	.651.6568
(Form	ner name or former address, if changed since last	report)
Check the appropriate box below if the Form 8-K fili following provisions:	ng is intended to simultaneously satisfy the filing	g obligation of the registrant under any of the
□ Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)		
□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)		
□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))		
□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))		
Indicate by check mark whether the registrant is an echapter) or Rule 12b-2 of the Securities Exchange Ad		of the Securities Act of 1933 (§230.405 of this
Emerging growth company $\square$		
If an emerging growth company, indicate by check mor revised financial accounting standards provided pu	•	tended transition period for complying with any new
Securities registered pursuant to Section 12(b) of the	Act:	
Title of each class	Trading symbol	Name of each exchange on which registered
Common Stock	OPRX	Nasdaq Capital Market

## **SECTION 8 – Other Events**

#### **Item 8.01 Other Events**

On May 29, 2020, we issued a press release concerning our invitation to present in William Blair & Company's 40th Annual Growth Stock Conference being held June 9-11, 2020. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 8.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

## **SECTION 9 – Financial Statements and Exhibits**

## **Item 9.01 Financial Statements and Exhibits**

99.1 Press release, dated May 29, 2020

# **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

# OptimizeRx Corporation

/s/ Douglas Baker
Douglas Baker
Chief Financial Officer

Date June 1, 2020



# OptimizeRx to Present at William Blair & Company's 40th Annual Growth Stock Conference, June 9-11, 2020

**ROCHESTER, Mich., (May 29, 2020)** — OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, payers and providers, has been invited to present in William Blair & Company's 40th Annual Growth Stock Conference being held June 9-11, 2020.

OptimizeRx CEO William Febbo is scheduled to present on June 10, 2020, at 9:20 a.m. Central time, as well as participate in virtual one-on-one meetings on the same day and June 11.

He will discuss a number of topics, including how OptimizeRx's record Q1 results demonstrated an acceleration in platform adoption and the further transformation of the company's revenue model into SaaS-based enterprise-level deployments. He will also discuss how COVID-19 has made OptimizeRx's nationwide digital connectivity at the point-of-care even more relevant to its customer base, which now includes the world's top 20 pharmaceutical companies.

The live presentation will be available at investors.optimizerx.com/events-and-presentations.

The event is for institutional clients of William Blair and is by invitation only. To schedule a one-on-one meeting with OptimizeRx, please contact your William Blair institutional sales representative. For further assistance or any questions about OptimizeRx, contact Ron Both of CMA at (949) 432-7557 or submit your inquiry here.

#### **About William Blair**

William Blair is a premier global boutique with expertise in investment banking, investment management, and private wealth management. The company provides advisory services, strategies, and solutions to meet its clients' evolving needs. As an independent and employee-owned firm, together with its strategic partners, William Blair operates in more than 20 offices worldwide. For more information, visit www.williamblair.com.

## About OptimizeRx®

OptimizeRx Corporation (NASDAQ: OPRX) is a digital health company that facilitates communication at point-of-care among all stakeholders in healthcare. Primarily focused on life science and payer clients, its suite of digital and mobile SaaS-based solutions enables affordability, patient adherence and care management. OptimizeRx's network reaches more than 60% of U.S. ambulatory providers, delivering therapeutic support on specialty medications and patient financial assistance directly within a provider's workflow through leading electronic health platforms. OptimizeRx's fully integrated platform supports the real-time exchange of information, improving provider knowledge and patient engagement, and ultimately leading to healthier outcomes.

For more information, go to OptimizeRx.com, and follow the company on Twitter and LinkedIn.

#### **Important Cautions Regarding Forward Looking Statements**

This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other material risks.

## **OptimizeRx Contact**

Doug Baker, CFO Tel (248) 651-6568 x807 dbaker@optimizerx.com

## **Media Relations Contact**

Maira Alejandra, Media Relations Manager Tel (754) 245-7070 malejandra@optimizerx.com

## **Investor Relations Contact**

Ron Both or Grant Stude CMA Investor Relations Tel (949) 432-7557 oprx@cma.team